Fig. 1

Flowchart summarizing the KEYNOTE-001 treatment cohorts in solid tumors, melanoma, and NSCLC that have been reported to date. Abbreviations: IPI ipilimumab; NSCLC non-small cell lung cancer; PD-L1 programmed death receptor ligand 1; Q2W once every 2 weeks; Q3W once every 3 weeks